Roche (VTX:ROG) received a CHF 260 price objective from stock analysts at UBS in a report issued on Wednesday, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the healthcare company’s stock. UBS’s price objective indicates a potential upside of 5.78% from the stock’s previous close.

ROG has been the topic of several other research reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the stock a “neutral” rating in a research note on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research note on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Roche in a research note on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research note on Friday, October 6th. Finally, Jefferies Group set a CHF 295 price objective on Roche and gave the stock a “buy” rating in a research note on Monday, October 16th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of CHF 261.32.

Roche (VTX:ROG) opened at CHF 245.80 on Wednesday. Roche has a 1-year low of CHF 219.10 and a 1-year high of CHF 273.

TRADEMARK VIOLATION NOTICE: “UBS Reiterates “CHF 260” Price Target for Roche (ROG)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/06/ubs-reiterates-chf-260-price-target-for-roche-rog.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.